Literature DB >> 32334985

Hepatitis B Virus Reactivation Potentiated by Biologics.

Eiichi Ogawa1, Mike T Wei2, Mindie H Nguyen3.   

Abstract

Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatitis B virus; Nucleos(t)ide analogue; Prophylaxis; Reactivation

Year:  2020        PMID： 32334985     DOI： 10.1016/j.idc.2020.02.009

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  8 in total

1.  Contribution of Biologic Response Modifiers to the Risk of Coccidioidomycosis Severity.

Authors:  Fariba M Donovan; Ferris A Ramadan; James R Lim; Julia E Buchfuhrer; Rebia N Khan; Natalie P DeQuillfeldt; Natalie M Davis; Ashwini Kaveti; Melanie De Shadarevian; Edward J Bedrick; John N Galgiani
Journal:  Open Forum Infect Dis       Date:  2022-01-27       Impact factor: 3.835

Review 2.  Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies.

Authors:  Tyler Ellis Smith; Ilya Kister
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-19       Impact factor: 5.081

Review 3.  Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations.

Authors:  Ping Ji; Jianmeng Chen; Amit Golding; Nikolay P Nikolov; Bhawana Saluja; Yunzhao R Ren; Chandrahas G Sahajwalla
Journal:  J Clin Pharmacol       Date:  2020-09-08       Impact factor: 2.860

4.  Late Hepatitis B reactivation after treatment with rituximab.

Authors:  Sara Lacerda Pereira; Raquel Duro; António Sarmento
Journal:  IDCases       Date:  2022-01-10

5.  TNFα Blockade Inhibits Both Initial and Continued Control of Pulmonary Coccidioides.

Authors:  Daniel A Powell; Lisa F Shubitz; Christine D Butkiewicz; Hien T Trinh; Fariba M Donovan; Jeffrey A Frelinger; John N Galgiani
Journal:  Front Cell Infect Microbiol       Date:  2022-01-31       Impact factor: 6.073

6.  Risk for Hepatitis B Virus Reactivation in Patients with Psoriasis Treated with Biological Agents: A Systematic Review and Meta-Analysis.

Authors:  Xinyu Wang; Ming Zhang; Yu Chen; Yirong Liu; Yan Yu; Xiaojie Huang; Yanqing Gao
Journal:  Dermatol Ther (Heidelb)       Date:  2022-01-29

Review 7.  COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature.

Authors:  Caterina Sagnelli; Laura Montella; Pierantonio Grimaldi; Mariantonietta Pisaturo; Loredana Alessio; Stefania De Pascalis; Evangelista Sagnelli; Nicola Coppola
Journal:  Pathogens       Date:  2022-07-21

8.  Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.

Authors:  Ying Ni; Lixia Gao; Yan Lu; Shiguang Ye; Lili Zhou; Wenbin Qian; Aibin Liang; Ping Li
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.